妊娠安全研究中数据收集的改进:妊娠报告数据元素标准化的ConcePTION项目
ConcePTION项目评估了多个公共和私人数据提供方将各自变量映射到妊娠药物安全核心数据元素(CDE)框架的能力。四个妊娠登记、两个增强药物警戒项目和四个致畸信息服务机构参与,结果显示多数数据变量可直接使用或衍生以符合CDE定义,表明不同利益相关方之间的数据协调和标准化分析是可行的。
要点
- 多数数据提供方变量可直接对应CDE,支持妊娠药物警戒数据标准化。
- 仅少数变量因定义分歧或缺失无法对齐,整体匹配度高。
- 该框架有望加速和加强妊娠安全数据的协同分析。
核心结论
- 参与研究的数据提供方变量与核心数据元素(CDE)匹配比例很高,表明不同利益相关方之间定义对齐和数据分析协调是可行的。
研究设计与样本
- 研究纳入四个妊娠登记(Gilenya、Aubagio、OTIS、荷兰妊娠药物登记)、两个增强药物警戒项目(Gilenya PRIM、MAPLE-MS)和四个致畸信息服务机构(英国TIS、耶路撒冷TIS、Zerifin TIS、瑞士TIS),评估其变量与CDE框架的映射能力。
- CDE框架包含51个项目,涵盖管理功能、妊娠描述、母亲病史、妊娠期疾病、分娩详情及妊娠和婴儿结局。
主要发现
- 多数数据提供方变量可直接取自原变量(85%,n=305/357,数据提供方间范围73-94%)或通过组合不同变量衍生(12%,n=42/357,范围0-24%)以符合CDE变量和定义。
- 极少数变量无法与CDE项目对齐,原因包括定义分歧(1%,n=3/357,范围0-2%)或变量不可用(2%,n=7/357,范围0-4%)。
临床怎么用
- 临床药学智能体医生可参考CDE框架,在妊娠用药安全数据收集和分析中促进多源数据的标准化与协调。
局限性
- 研究仅以多发性硬化症为试点,结果可能不适用于其他疾病领域。
- 参与的数据提供方数量有限,且未涵盖所有类型的妊娠数据源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVE: The ConcePTION project aims to improve the way medication use during pregnancy is studied. This includes exploring the possibility of developing a distributed data processing and analysis infrastructure using a common data model that could form a foundational platform for future surveillance and research. A prerequisite would be that data from various data access providers (DAPs) can be harmonised according to an agreed set of standard rules concerning the structure and content of the data. To do so, a reference framework of core data elements (CDEs) recommended for primary data studies on drug safety during pregnancy was previously developed. The aim of this study was to assess the ability of several public and private DAPs using different primary data sources focusing on multiple sclerosis, as a pilot, to map their respective data variables and definitions with the CDE recommendations framework. METHODS: Four pregnancy registries (Gilenya, Novartis; Aubagio, Sanofi; the Organization of Teratology Information Specialists [OTIS]; Aubagio, Sanofi; the Dutch Pregnancy Drug Register, Lareb), two enhanced pharmacovigilance programmes (Gilenya PRIM, Novartis; MAPLE-MS, Merck Healthcare KGaA) and four Teratology Information Services (UK TIS, Jerusalem TIS, Zerifin TIS, Swiss TIS) participated in the study. The ConcePTION primary data source CDE includes 51 items covering administrative functions, the description of pregnancy, maternal medical history, maternal illnesses arising in pregnancy, delivery details, and pregnancy and infant outcomes. For each variable in the CDE, the DAPs identified whether their variables were: identical to the one mentioned in the CDE; derived; similar but with a divergent definition; or not available. RESULTS: The majority of the DAP data variables were either directly taken (85%, n = 305/357, range 73-94% between DAPs) or derived by combining different variables (12%, n = 42/357, range 0-24% between DAPs) to conform to the CDE variables and definitions. For very few of the DAP variables, alignment with the CDE items was not possible, either because of divergent definitions (1%, n = 3/357, range 0-2% between DAPs) or because the variables were not available (2%, n = 7/357, range 0-4% between DAPs). CONCLUSIONS: Data access providers participating in this study presented a very high proportion of variables matching the CDE items, indicating that alignment of definitions and harmonisation of data analysis by different stakeholders to accelerate and strengthen pregnancy pharmacovigilance safety data analyses could be feasible.
引用
- Favre G, Richardson JL, Moore A, et al. Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project. Drug Saf. 2023. PMID: 38114757. doi:10.1007/s40264-023-01384-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。